Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -365.90M | -400.50M | -395.20M | -101.40M | -127.30M |
| Total Depreciation and Amortization | 53.70M | 55.90M | 58.90M | 59.90M | 61.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 333.30M | 384.30M | 384.30M | 81.00M | 111.80M |
| Change in Net Operating Assets | -19.30M | -41.90M | -70.60M | -45.90M | -54.40M |
| Cash from Operations | 1.80M | -2.20M | -22.60M | -6.40M | -8.70M |
| Capital Expenditure | -15.60M | -14.50M | -15.20M | -17.60M | -19.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 8.80M | 8.80M | 8.80M |
| Other Investing Activities | -11.80M | -12.80M | -7.20M | -4.30M | -1.70M |
| Cash from Investing | -27.40M | -27.30M | -13.60M | -13.10M | -11.90M |
| Total Debt Issued | 165.00M | 185.00M | 80.00M | 100.00M | 120.00M |
| Total Debt Repaid | -80.50M | -100.00M | -60.00M | -80.00M | -119.50M |
| Issuance of Common Stock | 3.30M | 5.60M | 5.60M | 5.90M | 5.90M |
| Repurchase of Common Stock | -7.30M | -7.30M | -10.00M | -10.50M | -13.40M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.30M | -8.80M | -400.00K | -400.00K | -400.00K |
| Cash from Financing | 64.20M | 74.50M | 15.20M | 15.00M | -7.40M |
| Foreign Exchange rate Adjustments | 800.00K | 0.00 | 1.20M | -100.00K | -1.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | 2.30M | 0.00 | 0.00 |
| Net Change in Cash | 39.40M | 45.00M | -17.50M | -4.60M | -29.00M |